Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Sarcoma: A Multicenter, Retrospective Study
Sarcoma · 15.11.2019 · 2019 · 1-7
DOI: 10.1155/2019/3158590 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sarcoma, erschienen am 15.11.2019. Verfasst von Prasad Narayanan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cytecare Cancer Hospitals, Yelahanka, Bengaluru, Karnataka 560064, India. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intas Pharmaceuticals Ltd..
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
To evaluate the efficacy and safety of nanosomal docetaxel lipid suspension (NDLS, DoceAqualip) based chemotherapy in patients with sarcoma.
Methods
In this retrospective, multicenter (6 centers), observational study, we analyzed the medical charts of adult patients of either sex, who were treated with NDLS (75 mg/m 2 in 3-weekly cycles) based chemotherapy for the treatment of sarcoma. The efficacy outcomes were overall response rate (ORR: complete response (CR) + partial response (PR)) and disease control rate (DCR: CR + PR + stable disease (SD)) in patients who received NDLS-based chemotherapy in neoadjuvant and metastatic settings. Overall survival (OS) and safety were evaluated for all settings.
Results
Of 11 patients (neoadjuvant: 1, adjuvant: 3, and metastatic: 7) in this study, majority had leiomyosarcoma (63.6%, 7/11) followed by extraskeletal myxoid chondrosarcoma (EMC), high grade pleomorphic sarcoma of mandible, malignant fibrous histiocytoma of right thigh, and osteosarcoma of femur (9.1% each, 1/11 each). NDLS plus gemcitabine combination was used in 10 patients (90.9%), and NDLS plus cyclophosphamide was used in one patient with EMC (9.1%). Efficacy evaluation was performed for 7 patients (neoadjuvant: 1/1; metastatic: 6/7). Complete response was reported in one patient (soft tissue sarcoma of mandible) treated in neoadjuvant setting. In metastatic setting, ORR was 50% and DCR was 66.7% (CR: 16.7% (1/6), PR: 33.3% (2/6), SD: 16.7% (1/6)). At a median follow-up of 6.5 months (range: 0.06–20.2 months), median OS was not reached in neoadjuvant and adjuvant settings, but it was 15.8 months in metastatic setting. At least 1 AE was reported in 7 (63.6%) patients. Neutropenia, thrombocytopenia, lymphopenia, and anemia were the hematological AEs, whereas nausea, vomiting, and diarrhea were the most common nonhematological AEs. NDLS treatment was well tolerated without any new safety concerns.
Conclusion
Nanosomal docetaxel lipid suspension-based chemotherapy was efficacious and well tolerated in the treatment of sarcoma. Further prospective trials are needed to confirm the data.
Autor:innen und Institutionen
- Cytecare Cancer Hospitals, Yelahanka, Bengaluru, Karnataka 560064, India.
- Omega Hospitals, Hyderabad, Telangana 500034, India.
- Department of Medical Oncology, CBCC-GVN Cancer Center, Tiruchirapalli, Tamil Nadu 620005, India.
- VS Hospital, Madras Cancer Institute, Advanced Cancer Care, Chennai, Tamil Nadu 600031, India.
- American Oncology Institute, Dayanand Medical College & Hospital, Ludhiana, Punjab 141001, India.
- Medical Affairs and Clinical Development, Intas Pharmaceuticals Ltd., Sola, Ahmedabad, Gujarat 380054, India.
ORCID-Profile: Imran Ahmad
Förderung
- Intas Pharmaceuticals Ltd.
Zitieren
APA
Narayanan, P., Dattatreya, P. S., Prasanna, R., Subramanian, S., Jain, K., Somanath, N. S., Joshi, N., Bunger, D., Khan, M. A., Chaturvedi, A., & Ahmad, I. (2019). Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Sarcoma: A Multicenter, Retrospective Study. Sarcoma, 2019, 1-7. https://doi.org/10.1155/2019/3158590
Vancouver
Narayanan P, Dattatreya PS, Prasanna R, Subramanian S, Jain K, Somanath NS, et al. Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Sarcoma: A Multicenter, Retrospective Study. Sarcoma. 2019;2019:1-7. doi:10.1155/2019/3158590
BibTeX
@article{Narayanan2019,
author = {Narayanan, Prasad and Dattatreya, Palanki Satya and Prasanna, Rammohan and Subramanian, Sundaram and Jain, Kunal and Somanath, Nirni Sharanabasappa and Joshi, Nisarg and Bunger, Deepak and Khan, Mujtaba Ali and Chaturvedi, Alok and Ahmad, Imran},
title = {Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Sarcoma: A Multicenter, Retrospective Study},
journal = {Sarcoma},
year = {2019},
volume = {2019},
pages = {1--7},
doi = {10.1155/2019/3158590}
}
EUVIMED